# Rebecca Dent

Source: https://onco.cc/people/rebecca-dent/  
OnCo record `rebecca-dent` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.

## Summary

Rebecca Dent is Deputy Chief Executive Officer for clinical operations at the National Cancer Centre Singapore and a senior consultant in medical oncology. Her research focuses on triple-negative and early breast cancer, and she has been a lead investigator on international phase 3 trials of immunotherapy and targeted agents in breast cancer. She chairs and contributes to international breast cancer guideline and consensus groups.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: leadership; clinician-scientist; breast cancer
- Role: Deputy Chief Executive Officer (Clinical)
- Specialisms: Breast cancer; Triple-negative breast cancer; Clinical trials

## Sources

- Institution profile: https://www.nccs.com.sg/about-nccs/leadership.html
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- institutions: [National Cancer Centre Singapore](https://onco.cc/institutions/nccs/)
- trials: [IMpassion130](https://onco.cc/trials/impassion130/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [TROPION-Breast02](https://onco.cc/trials/tropion-breast02/)
- journals: [Breast cancer research and treatment](https://onco.cc/journals/breast-cancer-research-and-treatment/)
- key papers: [Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial](https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/), [Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial](https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/), [Triple-negative breast cancer: clinical features and patterns of recurrence](https://onco.cc/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/rebecca-dent.json